WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01266083
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
- Conditions
- Acute Myeloid Leukemia (AML)MDS/AML
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 50000
- Registration Number
- NCT01252485
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H., Linz, Austria
Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2010-11-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT01247493
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Biological: Human Stem Cell Transplantation
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- University Hospital Carl Gustav Carus
- Target Recruit Count
- 143
- Registration Number
- NCT01246752
- Locations
- 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
🇩🇪Klinikum Chemnitz gGmbH, Chemnitz, Germany
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT01242774
- Locations
- 🇺🇸
Stanford University Medical Center Stanford U, Stanford, California, United States
🇺🇸Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
🇺🇸Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital, Columbus, Ohio, United States
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 144
- Registration Number
- NCT01237808
- Locations
- 🇩🇪
Ubbo-Emmius Klinik Aurich, Aurich, Germany
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪University Hospital of Bonn, Bonn, Germany
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01211457
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 4
- Registration Number
- NCT01198054
- Locations
- 🇪🇸
Hospital General de Alicante., Alicante, Spain
🇪🇸Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸Hospital Clínico y Provincial de Barcelona, Barcelona, Spain
Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- Taipei Medical University WanFang Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01195506
- Locations
- 🇨🇳
Taipei Medical University - WanFang Hospital, Taipei, Taiwan
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
- Target Recruit Count
- 252
- Registration Number
- NCT01191957
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
🇮🇹Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda Ospedaliera SS Antonio e Biagio, Alessandria, Italy